Benzinga | Jan 27, 2021 08:06AM EST

Bionano Genomics Highlights Chief Medical Officer Presentation At The Festival of Genomics & Biodata

SAN DIEGO, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) announced a presentation by Chief Medical Officer Dr. Alka Chaubey at The Festival of Genomics & Biodata where she presented evidence supporting her vision of Optical Genome Mapping (OGM) with Saphyr as a first line test in genetic disease and cancer. As a first line test, OGM would be the first test applied to diagnose the patient and to determine their prognosis and management strategy. Supported by a large body of data provided by Bionano customers and internal and external studies, she demonstrated that OGM detects all classes of structural variants (SVs) including actionable variants in cancer defined by the World Health Organization (WHO) and National Comprehensive Cancer Network (NCCN), most of which next-generation sequencing (NGS) fails to detect and currently need a combination of multiple cytogenetic methods for clinical analysis.